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Reliable in vitro islet quality assessment assays that can be performed routinely, prospec-
tively, and are able to predict clinical transplant outcomes are needed. In this paper we pres-
ent data on the utility of an assay based on cellular oxygen consumption rate (OCR) in
predicting clinical islet autotransplant (IAT) insulin independence (II). IAT is an attractive
model for evaluating characterization assays regarding their utility in predicting II due to an
absence of confounding factors such as immune rejection and immunosuppressant toxicity.
Methods
Membrane integrity staining (FDA/PI), OCR normalized to DNA (OCR/DNA), islet equiva-
lent (IE) and OCR (viable IE) normalized to recipient body weight (IE dose andOCR dose),
and OCR/DNA normalized to islet size index (ISI) were used to characterize autoislet prepa-
rations (n = 35). Correlation between pre-IAT islet product characteristics and II was deter-
mined using receiver operating characteristic analysis.
Results
Preparations that resulted in II had significantly higherOCR dose and IE dose (p<0.001).
These islet characterization methods were highly correlated with II at 6–12 months post-
IAT (area-under-the-curve (AUC) = 0.94 for IE dose and 0.96 forOCR dose). FDA/PI
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(AUC = 0.49) and OCR/DNA (AUC = 0.58) did not correlate with II. OCR/DNA/ISI may have
some utility in predicting outcome (AUC = 0.72).
Conclusions
Commonly used assays to determine whether a clinical islet preparation is of high quality
prior to transplantation are greatly lacking in sensitivity and specificity. While IE dose is
highly predictive, it does not take into account islet cell quality. OCR dose, which takes into
consideration both islet cell quality and quantity, may enable a more accurate and prospec-
tive evaluation of clinical islet preparations.
Introduction
Cell-based transplant therapies may offer a minimally-invasive alternative to solid organ trans-
plants for certain diseases such as diabetes. Islet transplantation is emerging as an attractive
therapy [1–4]. There is a critical need for reliable assays that assess the quality of clinical islet
preparations prior to transplantation, especially as islet transplant is more widely-applied
and becoming standard-of-care. Such assays would prevent transplantation of islet prepara-
tions of poor quality that would fail to reverse diabetes and would facilitate regulatory approv-
als. Currently-accepted product release criteria for clinical islet allotransplant include the islet
dose based on number of islet equivalents (IE) normalized to the recipient body weight (IE/
kg), fractional viability as estimated with membrane integrity staining using fluorescein diace-
tate/propidium iodide (FDA/PI), islet purity based on dithizone (DTZ) staining, and glucose
responsiveness as measured by static insulin release assays [5, 6]. However, clinical transplant
outcomes (CTOs) cannot be discerned based on these pre-transplant criteria [6]. These cur-
rently-available quality assessment assays are not fully reliable, exhibiting high false positive
rates when attempting to predict rates of insulin independence (II).
Islet dose normalized to recipient body weight presented in units of IE/kg has been reported
to correlate with clinical islet auto- and allotransplant outcomes [7–9] and threshold doses
have been established to try to increase the likelihood of a favorable CTO. However, there have
been numerous cases in which very high IE doses have failed to reverse diabetes, while low
doses were successful. Previously published intraportal islet autotransplant (IAT) data from
the University of Minnesota (n = 59) have shown that the IE dose correlates with CTOs [Fig 1,
receiver operating characteristic (ROC) analysis yields area-under-the-curve (AUC) of 0.82]
[10]. However, there was a high degree of overlap in IE doses resulting in either II or depen-
dence, as shown by the grey bar region in Fig 1. We hypothesized that the viable IE dose (or
OCR dose) may be more predictive of CTOs than the total IE dose. We utilized oxygen con-
sumption rate (OCR) measurements normalized to DNA (OCR/DNA, a measure of fractional
viability) to estimate the OCR dose (the product of the IE dose and OCR/DNA). To test this
hypothesis, we utilized the clinical IAT model, which is an attractive model for evaluating
characterization assays due to an absence of confounding factors such as immune rejection or
immunosuppressant toxicity.
OCR has been proposed as a means to evaluate islet quality [6, 11–15]. OCR measurements
performed using the stirred microchamber system are accurate, quantitative, operator-inde-
pendent, and can be performed prospectively [13–15]. Since the technology has been devel-
oped, data have been generated that correlate islet OCR and OCR/DNA measurements (when
these parameters are used in combination) and transplant outcomes with the nude mouse
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bioassay [13, 15]. In these animal studies, graft function (or non-function) could be associated
with discrete regions defined by measurements of OCR and OCR/DNA done on islet prepara-
tions prior to transplant. Recently published work by our group showed that OCR dose was
able to predict transplant outcome in a small number of cases using the human allotransplant
model (donor islets transplanted into type 1 diabetic recipients) [16]. The present study is the
first publication to explore the use of OCR dose to predict CTO following islet autotransplanta-
tion (non-diabetic pancreatitis patients transplanted with their own islets).
Materials and Methods
Study Design
Data from patients experiencing severe pancreatitis who underwent total pancreatectomy (TP)
and IAT at the University of Minnesota from June 2005 to October 2009 were studied herein.
Only patients with 6–12 months of post-IAT follow-up and available pre-IAT OCR measure-
ments were included in the analysis (n = 35). Exclusion criteria were pre-existing diabetes mel-
litus or impaired glucose tolerance, or prior partial pancreatectomy with IAT. II was defined as
fasting blood glucose level (BGL)<126 mg/dL, 2-hour postprandial BGL<180 mg/dL, and
hemoglobin A1C (HbA1C)6.5% without use of exogenous insulin. We examined the utility
of 5 different pre-IAT islet product characteristics [FDA/PI, OCR/DNA, OCR/DNA normal-
ized to the islet size index (ISI), IE dose and OCR dose] to predict post-IAT II rates.
Ethics statement
The present study was approved by the University of Minnesota Institutional Review Board
(UMN-IRB). Patients transplanted prior to September 2006 were covered under UMN-IRB
protocol #0511M77516 with verbal consent obtained by telephone. The patient was mailed the
informed consent in advance, and the investigator obtained informed consent subsequently by
telephone. This study was a retrospective assessment of outcomes which included medical rec-
ords review and a telephone questionnaire. Because patients did not have any onsite study visit,
and the study risk was minimal, the UMN-IRB approved obtaining consent by telephone as
described. Patients transplanted following September 2006 were covered under UMN-IRB
Fig 1. Previously published data showing overlap and correlation of islet equivalent dose with clinical transplant outcome.Data from Anazawa
et al. [10] illustrating that the islet equivalent (IE) dose correlates with the clinical outcome [insulin independence vs. dependence] at 6–12 months following
islet autotransplant (IAT). However, the gray region indicates a wide range of IE dose (IE/kg of recipient) that is associated with an uncertain IAT outcome.
The second graph shows the receiver operating characteristic (ROC) curve for this previously published data set with the area-under-the-curve (AUC) above.
doi:10.1371/journal.pone.0134428.g001
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protocol #0609M91887 with written consent obtained and documented on an informed con-
sent form and in the patient’s medical records.
Total pancreatectomy, islet isolation and purification
TP-IAT was performed as described previously [17]. Briefly, TP was done to preserve the
blood supply to the pancreas until immediately before resection to minimize warm ischemia
time. Following TP, the pancreas was surface-cooled and transported to the islet isolation labo-
ratory. The basic method for islet isolation and purification has been described previously [17].
Each pancreas was distended by an intraductal infusion of collagenase solution and then
digested at 37°C using the Ricordi method [18]. After digestion, the islet preparation may have
been additionally purified by density gradient centrifugation. The decision to purify the islet
preparation was based on the post-digest tissue volume (TV), with>0.25 cm3/kg (volume per
kilogram recipient body weight) generally serving as an indication for purification.
Islet product characterization
Aliquots of islet product were manually counted using an inverted light microscope to estimate
the total number of islet particles (IPs) of>50 μm in diameter in the entire preparation. Based
on stratifying each IP into an approximate size range (50–100 μm, 100–150 μm, etc.) during
the manual count, the total number of IPs in the preparation was converted to a total number
of IEs to account for differences in islet size. This was done by assuming that a perfectly spheri-
cal 150 μm diameter islet represented the volume of 1 IE [5]. The total number of IEs per kilo-
gram recipient body weight (IE/kg) was defined as the IE dose. A visual estimate of purity was
performed by estimating the percent of insulin-producing cells stained by DTZ [19]. Further-
more, ISI (a dimensionless quantity) was calculated by dividing the total number of IEs in a
preparation by the total number of IPs. ISI provides a simple metric that reflects the average
size of an IP in a preparation [20, 21].
All preparations were evaluated for their fractional viability by differential membrane integ-
rity staining with FDA/PI [5]. OCR/DNA was measured approximately 1–4 hours post-isola-
tion when sufficient IE were isolated; the technique has been previously described in detail
[13–15]. Average fractional viabilities from multiple measurements were reported (n = 2 to 4).
OCR/DNA is a measure of fractional viability since DNA is stable, even in dying tissue over
>24 hours [22], and its content per IE is reliably constant [5]. Based on promising data in a
recent literature report, the mean OCR/DNA value of an islet preparation was normalized to
the ISI, giving a separate pre-IAT quality assessment metric of OCR/DNA/ISI (with same units
as OCR/DNA; nmol O2
minmg DNA) [23].
The viable IE dose (or OCR dose) was calculated from the IE dose and OCR/DNA. IE dose
was converted to an amount of DNA after multiplying by the conversion factor of 10.4 ng
DNA per IE [5]. The DNA dose in the transplanted preparation was then multiplied by the
mean OCR/DNA value to yield an OCR dose (in units of nmol O2/min•kg recipient body
weight; nmol O2
minmg DNA  10:4 ng DNAIE  mg1x106 ng  IEkg).
Islet autotransplantation
The typical autoislet product preparation time ranged from 3.5–6.5 hours. Islet products were
suspended in Connaught Medical Research Laboratories (CMRL)-1066 transplant medium
(Mediatech Inc., Manassas, VA) supplemented with 25mMHEPES, antibiotics, and 2.5% m/v
human serum albumin and transferred to the operating room. Heparin (70 units/kg) was
administered systemically and the islet product was directly infused under gravity into the
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portal vein over a 15–60 minute period. During the infusion, the portal pressures were continu-
ously monitored and if they exceeded 25 cm H2O the remainder of the islet preparation was
infused into the peritoneal cavity. All patients were placed on an insulin drip in the immediate
post-operative period, which was transitioned to subcutaneous insulin injections at ~1 week
post-operatively. Target BGLs have been summarized elsewhere [24].
Statistical analysis
Relationships between pre-IAT islet product characteristics and CTOs were examined using
ROC curve analysis. The AUC was calculated from ROC curves generated for each islet prod-
uct characteristic and these values were evaluated. We analyzed several multivariate models
and additionally included age, BMI, and purity to the model. A backward selection was used
and we assessed the goodness of the models with the AUC of the ROC curve. In addition, we
compared the models using the Akaike information criterion (AIC) values with a smaller AIC
value standing for a better model. Statistical significance corresponded to p-values<0.05. All
statistical analyses were performed using SAS statistical software package, version 9.3 (SAS
Institute Inc., Cary, NC) or GraphPad Prism Version 5.03 (GraphPad Software Inc., La Jolla,
CA).
Results
There were significant differences in BMI (p = 0.006), IE/g trimmed pancreas weight (p =
0.05), purity (p = 0.02), and ISI (p = 0.009) between patients achieving II versus those with
insulin dependence 6–12 months post-IAT (Table 1). For islet characterization methods, there
were no significant differences in FDA/PI (p = 0.96) or OCR/DNA (p = 0.48). However, there
were significant differences in the OCR/DNA/ISI (p = 0.043), IE dose (p< 0.001) and OCR dose
(p< 0.001) between groups. The grey regions in Fig 2 illustrate values of overlap between CTO




N 25 10 -
% female 76% 80% -
Age (years) 39 ± 2 31 ± 5 0.139
BMI (kg/m2) 26 ± 1 21 ± 0.9 0.006a
Trimmed pancreas weight (g) 74 ± 7 72 ± 8 0.956
IE/g pancreas 3,579 ± 517 6,393 ± 897 0.046a
Purity (%) 27 ± 3% 44 ± 7% 0.019a
Tissue volume (TV; mL) 10 ± 1 13 ± 3 0.674
Islet size index (ISI) 0.86 ± 0.06 1.2 ± 0.1 0.009a
FDA/PI (% viable) 92 ± 1% 92 ± 2% 0.956
OCR/DNA (nmol O2/min•mg DNA) 110 ± 6 115 ± 5 0.476
OCR/DNA/ISI (nmol O2/min•mg DNA) 140 ± 10 104 ± 12 0.043
1a
IE dose (IE/kg) 3,800 ± 250 7,500 ± 660 < 0.001a
OCR dose (nmol O2/min•kg) 4.3 ± 0.3 8.9 ± 0.9 < 0.001
a
Data are means ± standard error or percentage.
asigniﬁcant difference (p< 0.05) between groups as calculated by a Mann Whitney non-parametric test.
doi:10.1371/journal.pone.0134428.t001
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Fig 2. Overlap and correlation of islet characterization methods with clinical transplant outcome. Data
from our study illustrating that membrane integrity staining (based on FDA/PI), oxygen consumption rate
(OCR) normalized to DNA content (OCR/DNA), and OCR/DNA normalized to the islet size index (ISI) (OCR/
DNA/ISI) are not correlated with the clinical outcome [insulin independence vs. dependence] at 6–12 months
OCR Predicts Islet Autotransplantation Outcome
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that may poorly predict post-IAT outcomes for IE/kg and OCR/kg. More cases fell in the grey
region of uncertainty for IE/kg (n = 13) than OCR/kg (n = 7). In cases #25, 32, 33 and 35 which
had a high IE dose that did not result in II, the OCR dose was able to correctly classify the CTO
(Table 2). The same was true in case #11 with low IE dose and high OCR dose in a patient
achieving II. For IE dose, the rate of correct estimation was 94% with a sensitivity of 0.9 and
specificity of 0.92, and the calculated cut-off point for CTO was 5,794 IE/kg. For OCR dose, the
rate of correct estimation was 96% with a sensitivity of 1.0 and specificity of 0.88, and the calcu-
lated cut-off point for CTO was 6.23 nmol/min•kg. Similarly, ROC analysis indicated that
FDA/PI (AUC = 0.49) and OCR/DNA (AUC = 0.58) were not predictive of post-IAT out-
comes, while OCR/DNA/ISI (AUC = 0.72) was somewhat predictive (Fig 2). IE dose and OCR
dose were highly predictive of post-IAT outcomes, with OCR dose having better predictive abil-
ity (AUC of 0.96 vs. 0.94 with IE dose). No significant difference could be found between the
AUCs for IE dose and OCR dose. For the different multivariate models, none of the additional
variables reached any measurable impact. Age seems to have a slight impact as there was a sig-
nificant negative correlation between IE dose, OCR dose and age.
Discussion
As islet transplantation moves closer to becoming standard-of-care, in vitro islet quality assess-
ment assays that can be performed routinely and prospectively to predict CTOs are needed. In
our study, we present data on the utility of an assay based on cellular OCR which may be help-
ful in predicting rates of II in clinical IAT. Both IE dose and OCR dose were highly predictive of
CTO. The IE dose in our cohort of patients was more predictive of CTO than a past cohort pre-
sented by Anazawa et al [10]. Therefore, it is possible that in a larger cohort OCR dose would
be significantly more predictive than IE dose especially in those patients who receive a marginal
IE dose as illustrated in Table 2.
The concept of transplanting an adequate IE dose to achieve II is intuitive, and it has been
proven to be important in clinical practice [1, 2, 4, 7–9, 25–28]. Based on experience and data
with clinical intraportal transplantation, the minimum required dose to consistently achieve
diabetes reversal has been found to be approximately 5,000 IE/kg for IAT [8, 9, 17, 29] and
10,000 IE/kg for islet allotransplant [1, 2, 4, 8, 25–28]. The effect of viability also has been rec-
ognized and islet membrane integrity (as measured by FDA/PI staining) is a standard islet
following islet autotransplant (IAT). However, both islet equivalent (IE) dose and theOCR dose were
correlated with post-IAT outcome. The gray region indicates the range of IE andOCR doses that is
associated with uncertain IAT outcome. Note that the width of the gray region is much narrower with theOCR
dose. The black dotted line represents the calculated cut-off point for clinical outcome (IE dose: 5,794 and
OCR dose: 6.23). The second column of graphs represents receiver operating characteristic (ROC) curves
for each of the five islet product characteristics from this data set. The area-under-the-curve (AUC) has been
calculated for each islet product characteristic and these values are shown above each ROC curve.
doi:10.1371/journal.pone.0134428.g002
Table 2. Summary of cases whereOCR dose correctly predicted clinical transplant outcome, whereas IE dose did not.
Case # OCR/DNA (nmol O2/min•mg DNA) OCR dose (nmol O2/min•kg) IE dose (IE/kg) Insulin status at 6–12 months
25 76 4.1 5,199 Dependent
33 96 5.1 5,314 Dependent
35 88 6.0 6,586 Dependent
32 97 6.2 6,147 Dependent
11 142 6.5 4,414 Independent
doi:10.1371/journal.pone.0134428.t002
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product release criterion. There are two major limitations in the current approach: 1) the mini-
mum IE dose is not adjusted for islet product viability, and 2) the currently-used viability assay
(FDA/PI) is insensitive [5, 6, 13]. An islet viability value<70% is rarely reported, which may
indicate to some that there is no need to make an adjustment for islet product viability when
considering the IE dose. However, recent reports with more reliable islet viability assays, such
as OCR/DNA [6, 13, 14], demonstrate that there is large variability in islet viability as measured
by OCR/DNA but not as measured by FDA/PI, and suggest the need to account for viability in
the IE dose.
We have previously used the mouse bioassay to study the utility of OCR and OCR/DNA to
predict diabetes reversal with high-purity human and rat islet preparations [13, 15]. Published
results demonstrate that when used together these parameters can predict diabetes reversal in
mice with high specificity and sensitivity. When used in combination with OCR dose, OCR/
DNA values of 150 nmol O2/min•mg DNA provided a reliable threshold above which diabetes
reversal was predicted in rat islet transplants into immunosuppressed mice [16]. However, in
this study, OCR/DNA alone was not predictive of CTOs (Fig 2D). A reason may be in the dif-
ference in the transplant site (renal subcapsule in mice vs. liver in humans). Preparations with
low OCR/DNA indicate a larger fraction of dead or dying tissue. It may be that transplanting
large quantities of dead or dying tissue into a confined space, such as under the renal capsule,
may more greatly impact the engraftment of the viable tissue by sequestering an inflammatory
response directly into the site of transplant and or by increasing the diffusional distance for
oxygen. This same phenomenon may not occur following intraportal transplant since the tissue
is not confined to a small space, but rather distributed throughout a large organ. In our study,
OCR dose was highly predictive despite the wide range of product purity in the preparations
examined (10–95%). Interestingly the data showed recipients that achieved II had a signifi-
cantly higher purity than those who were dependent 6–12 months post-IAT (Table 1) suggest-
ing that low purity may be associated with worse transplant outcomes.
Initial observations at the University of Minnesota suggest that a larger transplanted TV
(typically due to lower purity) may itself be associated with worse CTOs. Our group has found
that large TVs result in increased post-IAT portal pressures, which are directly associated with
higher complication rates (portal venous thrombosis and bleeding). In a separate ROC analysis
of a large cohort of TP-IAT patients (n = 233), our group has identified an increased risk of
portal venous thrombosis at>26 cm H2O, which is more likely to be exceeded with trans-
planted TVs of>0.25 mL/kg [30]. Since data on TV is collected for all preparations, use of
information on TV may enhance the predictive utility of IE and/or OCR doses and should be
studied further.
Islet size has also been implicated as predictive, with smaller islets expected to result in bet-
ter CTO, especially at a marginal IE dose. In a recent publication [19], patients who achieved II
had a significantly smaller ISI (i.e. on average islets with diameter smaller than 150 microme-
ters). Islet size in combination with OCR/DNA (OCR/DNA/ISI) was also recently associated
with better outcomes in a porcine islet to mouse xenograft model [22]. In this model, higher
OCR/DNA/ISI was associated with a greater probability for diabetes reversal. In the cohort of
patients reported in the present study, the results were contradictory as ISI was significantly
higher and OCR/DNA/ISI was significantly lower in patients who achieved II and the OCR/
DNA/ISI ratio was not as good at predicting CTO as IE or OCR dose. We do not have a clear
explanation for this difference, but it is conceivable that the effect of islet size is marginalized
when very high IE doses are transplanted. In other words, the total number of viable and func-
tional β-cells transplanted (e.g. at the periphery of larger islets) exceeds the minimum number
required for II, and more than accounts for the number of non-viable and/or non-functional
β-cells within the core of the larger islets. However, in a marginal IE dose transplant, having
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smaller islets with a minimized number of hypoxic β-cells in their core may have a substantial
impact on CTO [19, 20].
There are some limitations of this study. Calculation of the OCR dose is based on the IE dose
and thus the values have some inherent uncertainty since they are based on operator-depen-
dent manual counts. In addition, rather than correlating OCR dose only with categorical CTOs,
it may also be appropriate to quantify the reduction in exogenous insulin requirements and
also account for recipient factors, such as varying insulin sensitivity between individuals. These
improvements will aid in the case of islet allotransplant, as we predict that this model will be
more difficult to correlate CTO with characterization assays due to confounding factors such
as the need for immunosuppression therapy, potential rejection, and the high possibility of
multiple preparations being transplanted into a single recipient.
In conclusion, these data suggest that FDA/PI and OCR/DNA are not predictive of CTO
following IAT, while OCR/DNA/ISI may be of some utility. When IE dose (which is predictive
of CTO) is combined with the qualitative assay OCR/DNA (OCR dose), we are able to achieve
a highly predictive measurement which may be useful for the prospective evaluation of the
quality of islet preparations prior to clinical transplantation. Future studies will involve opti-
mizing the predictive capability of OCR dose in the IAT model and examining the utility of
these islet product characteristics, specifically OCR dose, on the more challenging case of
islet allotransplant.
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